Liver Transplantation and Metastatic Colo-rectal Cancer.
Survival, time to progression, other malignancy, side-effects, quality of life.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Survival
6 years
No
Svein Dueland, MD, PhD
Principal Investigator
Rikshospitalet-Radiumhospitalet RRHF
Norway: South region committee for research ethics in Norway
S-05409 (SECA I)
NCT00294827
February 2006
May 2020
Name | Location |
---|